Ventyx Investor Says Co. Overhyped Psoriasis Drug
Ventyx investors filed a proposed securities class action in California federal court on Friday, alleging the biopharma company made misleading statements regarding the efficacy and commercial prospects of its candidate inhibitor...To view the full article, register now.
Already a subscriber? Click here to view full article